This article is more than 5 years old. Information may no longer be current.
Synthetic retinoid derivative may reduce geographic atrophy secondary to AMD
Click Here to Manage Email Alerts
Fenretinide reduced the growth of geographic atrophy lesions secondary to atrophic age-related macular degeneration, according to a study.
“Collectively, the data from this trial provide compelling support for further investigations of the therapeutic potential of fenretinide in the treatment of AMD,” the study authors said.
The pathogenesis of geographic atrophy has been attributed to excess accumulation of retinol-based toxins. Investigators set out to determine the extent to which retinol reduction would effectively manage geographic atrophy. Orally administered fenretinide antagonizes serum retinol-binding protein, reducing retinol delivery to the eye.
The phase 2, randomized, multicenter trial included 246 patients with refractory geographic atrophy. Eighty patients received a daily 100-mg dose of fenretinide, 84 patients received a daily 300-mg dose, and 82 patients received placebo. Median patient age was 80 years.
Study results showed that fenretinide yielded dose-dependent, reversible reductions in lesion growth rates. Reduction of the yearly lesion growth rate was greater in the 300-mg dose group than in the placebo group. although the difference was not statistically significant.
Both dosages of fenretinide also reduced the incidence of choroidal neovascularization.
“This therapeutic effect was not dose dependent and is consistent with anti-angiogenic properties of fenretinide, which have been observed in other disease states,” the authors said.
Click Here to Manage Email Alerts